Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging Study of ADX48621 (Dipraglurant) Receptor Occupancy
NCT02447640Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Apr 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dipraglurant in Parkinson's disease (PD) (2 arms), sponsored by Johns Hopkins University. Primary endpoint: Maximum receptor occupancy and EC 50 for the receptor occupancy/ADX48621 plasma concentration relationship at Day 1. Started Apr 2015; status: completed.
02
Drugs
dipraglurant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02447640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02447640.